Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Cesar E. Mendoza is active.

Publication


Featured researches published by Cesar E. Mendoza.


Journal of Cardiovascular Pharmacology and Therapeutics | 2003

Reversal of refractory congestive heart failure after thiamine supplementation: report of a case and review of literature.

Cesar E. Mendoza; Francisco Rodriguez; Donald G. Rosenberg

Patients with refractory heart failure comprise a very important subgroup of patients with congestive heart failure. Before assuming that this condition simply reflects advanced, perhaps terminal, myocardial dysfunction, potentially reversible factors should be sought carefully. We describe a 58-year-old Hispanic man with a diagnosis of idiopathic dilated cardiomyopathy who presented with symptoms of severe congestive heart failure, glossitis, and peripheral neuropathy. His hemodynamic profile was characterized by refractory low-output cardiac failure and decreased vascular resistance. Thiamine deficiency was documented by a high thiamine pyrophosphate effect. His clinical condition was quickly reversed with thiamine administration. This response to thiamine administration supports the diagnosis and indicates that thiamine deficiency may play an important etiologic role in the deterioration of cardiac function in some patients with congestive heart failure.


Catheterization and Cardiovascular Interventions | 2004

Noncardiac surgery following percutaneous coronary intervention

Cesar E. Mendoza; Salim S. Virani; Neerav Shah; Alexandre Ferreira; Eduardo de Marchena

Patient with Coronary artery disease (CAD) undergoing major noncardiac surgery (NCS) are at increased risk of serious perioperative cardiac complications. At the same time, safety of percutaneous coronary intervention (PCI) before noncardiac surgery has been questioned. This paper reviews the available literature regarding the safety of PCI before NCS. At the same time, cardiac evaluation before NCS, perioperative medical management of patients undergoing NCS, and percutaneous coronary intervention and timing of NCS is also discussed. Catheter Cardiovasc Interv 2004;63:267–273.


Platelets | 2017

In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention.

Aaron E. Brice; Gabriel A. Hernandez; Mariluz Sanchez; Marshall Haynick; Cesar E. Mendoza

Abstract Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker has been proven to reduce subsequent cardiovascular events and in-stent thrombosis in patients undergoing percutaneous coronary intervention. Newer P2Y12 antagonists with faster onset and greater inhibition of platelet activity have improved cardiovascular outcomes but have created uncertainty with the appropriate dosing when switching between agents. Currently, there are no evidence-based guidelines to aid clinicians when switching between P2Y12 receptor blockers. Here we describe two patients that developed in-stent thrombosis when switching from ticagrelor to clopidogrel using a 300 mg clopidogrel loading dose. Both patients presented with ST elevation myocardial infarction and underwent stent placement but then developed in-stent thrombosis 48 hours after switching from ticagrelor to clopidogrel. These cases illustrate the severe consequences of suboptimal platelet inhibition and the need for prospective trials thoroughly powered to assess clinical outcomes in order to determine the most appropriate strategy when switching from ticagrelor to clopidogrel.


Netherlands Heart Journal | 2009

Clinical significance, angiographic characteristics, and short-term outcomes in 30 patients with early coronary artery graft failure

Salim S. Virani; Mahboob Alam; Cesar E. Mendoza; H. Arora; Alexander Ferreira; E. De Marchena

BackgroundDespite technical advances in coronary artery bypass grafting (CABG), early postoperative myocardial ischaemia still remains a challenging problem. The aim of this study was to determine the incidence, clinical features, angiographic characteristics, and management of early graft failure in the present CABG era.MethodsBetween January 1997 and December 2002, 1731 patients underwent CABG at our institution. Coronary angiography was performed in patients with clinical evidence of early postoperative ischaemia (≤3 months). Thirty of these patients with graft failure constituted the population of this study.ResultsOff-pump and on-pump CABG were almost evenly performed in these patients [n=16 (53%) and n=14 (47%) respectively]. Acute myocardial infarction and unstable angina were the leading indications for coronary angiography in the majority of patients [n=28 (93%)]. The most common cause of graft failure was occlusion / thrombosis [n=20 (67%)]. Percutaneous coronary intervention (PCI) was offered to the majority of patients [n=22 (73%)]. Of these patients, 14 underwent PCI to native coronary arteries, whereas eight underwent PCI to the culprit vessel. Three patients underwent reoperation, and five received medical management. Four patients (13%) died in hospital (two after redo CABG, one after unsuccessful PCI, and one patient managed medically). Two patients (7%) had nonfatal major complications (one non-ST-elevation myocardial infarction and one stroke).ConclusionEarly graft failure generally presents as acute coronary syndrome. Graft occlusion/ thrombosis is the leading cause of ischaemia. Patients with graft failure can undergo PCI with a relatively low risk, but the need for redo CABG in associated with a high mortality. (Neth Heart J 2009;17:13-7.)


The Journal of Thoracic and Cardiovascular Surgery | 2018

Endovascular crossover perfusion of lower limb in patients supported on veno-arterial extracorporeal membrane oxygenation: rescue therapy or thoughtful approach

Ali Ghodsizad; Cynthia M. Lai; April A. Grant; Cesar E. Mendoza; Matthias Loebe; Michael M. Koerner; Amit Badiye

Abstract There has been a dramatic increase in the use of Veno-Arterial Extracorporeal Membrane Oxygenation (VA ECMO) for hemodynamic support. Limb ischemia is a known complication of peripheral cannulation and an antegrade perfusion cannula can be inserted into the femoral or superficial femoral artery to minimize the risk of peripheral limb ischemia. Often, it is difficult to obtain antegrade access for limb perfusion due to anatomical or technical difficulties. Herein we report 5 cases in which a unique limb perfusion strategy was utilized using contralateral access for limb perfusion, as antegrade access was not feasible. To our knowledge, this is the first reported series of this approach.


Texas Heart Institute Journal | 2001

The role of interleukin-6 in cases of cardiac myxoma. Clinical features, immunologic abnormalities, and a possible role in recurrence.

Cesar E. Mendoza; Manuel Francisco Rosado; Leon Bernal


Texas Heart Institute Journal | 2007

Takotsubo cardiomyopathy, or broken-heart syndrome.

Salim S. Virani; A. Nasser Khan; Cesar E. Mendoza; Alexandre Ferreira; Eduardo de Marchena


Texas Heart Institute Journal | 2003

Graves' Disease and Pulmonary Hypertension: Report of 2 Cases

Salim S. Virani; Cesar E. Mendoza; Alexandre Ferreira; Eduardo de Marchena


The Journal of Thoracic and Cardiovascular Surgery | 2001

Interleukin-6 production and recurrent cardiac myxoma.

Cesar E. Mendoza; Manuel Francisco Rosado; Primo Pacheco


Texas Heart Institute Journal | 2007

Multiple Recurrences of Nonfamilial Cardiac Myxomas: A Report of Two Cases

Cesar E. Mendoza; Erik Bernstein; Alexandre Ferreira

Collaboration


Dive into the Cesar E. Mendoza's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Salim S. Virani

Baylor College of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge